Is your organization missing from this list? Reach out to Noelle Stango, Strategic Alliance Partnership Manager, to learn more about the complimentary strategic partnership program: nstango@mjhlifesciences.com
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer